RT Journal Article
SR Electronic
A1 Cunningham, Muriel
T1 EU-PACT Study: Initial Warfarin Dosing Improved by Clinical Variables and Genotype to Guide Therapy
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 20
SP 19
OP 19
DO 10.1177/155989771320009
UL http://mdc.sagepub.com/content/13/20/19.abstract
AB Response to warfarin is highly variable, making it difficult to select the optimal dose. Typical doses can range from 0.5 to 20 mg per day, and various factors, such as genetics, can influence an individual's daily dose. The purpose of the European Union Pharmacogenetics of Anticoagulant Therapy Warfarin Study [EU-PACT; Pirmohamed M et al. N Engl J Med 2013] was to compare whether the use of clinical variables and genotype information improves the time in therapeutic range compared with “standard” dosing.